FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000081737> ?p ?o ?g. }

• W3000081737 endingPage "358" @default.
• W3000081737 startingPage "358" @default.
• W3000081737 abstract "<h3>Importance</h3> A randomized clinical trial is needed to determine whether the second-generation Abl–tyrosine kinase inhibitor dasatinib is more effective than the first-generation inhibitor imatinib mesylate for childhood Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). <h3>Objective</h3> To determine whether dasatinib given at a daily dosage of 80 mg/m²is more effective than imatinib mesylate at a daily dosage of 300 mg/m²to improve event-free survival of children with Philadelphia chromosome–positive ALL in the context of intensive chemotherapy without prophylactic cranial irradiation. <h3>Design, Setting, and Participants</h3> This open-label, phase 3 randomized clinical trial was conducted at 20 hospitals in China. Enrollment occurred from January 1, 2015, through September 18, 2018, and randomization was stopped on October 4, 2018, when the early stopping criterion of the trial was met. Patients aged 0 to 18 years were recruited. Of the 225 patients with the diagnosis, 35 declined participation and 1 died before treatment, leaving 189 patients available for analysis. Data were analyzed from January 1 through August 4, 2019. <h3>Interventions</h3> Patients were randomized to receive daily dasatinib (n = 92) or imatinib (n = 97) continuously for the entire duration of ALL therapy from the time of diagnosis made during remission induction to the end of continuation therapy. <h3>Main Outcomes and Measures</h3> The primary outcome was event-free survival, analyzed based on intention to treat. The secondary outcomes were relapse, death due to toxic effects, and overall survival. <h3>Results</h3> Among the 189 participants (136 male [72.0%]; median age, 7.8 [interquartile range (IQR), 5.2-11.3] years) and a median follow-up of 26.4 (IQR, 16.3-34.1) months, the 4-year event-free survival and overall survival rates were 71.0% (95% CI, 56.2%-89.6%) and 88.4% (95% CI, 81.3%-96.1%), respectively, in the dasatinib group and 48.9% (95% CI, 32.0%-74.5%;<i>P</i> = .005, log-rank test) and 69.2% (95% CI, 55.6%-86.2%;<i>P</i> = .04, log-rank test), respectively, in the imatinib group. The 4-year cumulative risk of any relapse was 19.8% (95% CI, 4.2%-35.4%) in the dasatinib group and 34.4% (95% CI, 15.6%-53.2%) in the imatinib group (<i>P</i> = .01, Gray test), whereas the 4-year cumulative risk of an isolated central nervous system relapse was 2.7% (95% CI, 0.0%-8.1%) in the dasatinib group and 8.4% (95% CI, 1.2%-15.6%) in the imatinib group (<i>P</i> = .06, Gray test). There were no significant differences in the frequency of severe toxic effects between the 2 treatment groups. <h3>Conclusions and Relevance</h3> Intensive chemotherapy including dasatinib at a dosage of 80 mg/m²per day yielded superior results in the treatment of Philadelphia chromosome–positive ALL compared with imatinib mesylate at a dosage of 300 mg/m²per day and provided excellent control of central nervous system leukemia without the use of prophylactic cranial irradiation. <h3>Trial Registration</h3> Chinese Clinical Trial Registry:ChiCTR-IPR-14005706" @default.
• W3000081737 created "2020-01-23" @default.
• W3000081737 creator A5000726024 @default.
• W3000081737 creator A5003759585 @default.
• W3000081737 creator A5006824054 @default.
• W3000081737 creator A5014676719 @default.
• W3000081737 creator A5018363328 @default.
• W3000081737 creator A5020088480 @default.
• W3000081737 creator A5020660748 @default.
• W3000081737 creator A5020924929 @default.
• W3000081737 creator A5024662505 @default.
• W3000081737 creator A5030981796 @default.
• W3000081737 creator A5033718291 @default.
• W3000081737 creator A5036392227 @default.
• W3000081737 creator A5036713963 @default.
• W3000081737 creator A5037796472 @default.
• W3000081737 creator A5038550266 @default.
• W3000081737 creator A5044030725 @default.
• W3000081737 creator A5044084703 @default.
• W3000081737 creator A5049579176 @default.
• W3000081737 creator A5050284408 @default.
• W3000081737 creator A5050733356 @default.
• W3000081737 creator A5050892306 @default.
• W3000081737 creator A5055160753 @default.
• W3000081737 creator A5055585688 @default.
• W3000081737 creator A5057538695 @default.
• W3000081737 creator A5059665113 @default.
• W3000081737 creator A5062161921 @default.
• W3000081737 creator A5063641621 @default.
• W3000081737 creator A5071092152 @default.
• W3000081737 creator A5080177510 @default.
• W3000081737 creator A5082600835 @default.
• W3000081737 creator A5089102300 @default.
• W3000081737 date "2020-03-01" @default.
• W3000081737 modified "2023-10-07" @default.
• W3000081737 title "Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia" @default.
• W3000081737 cites W1498271295 @default.
• W3000081737 cites W1510901763 @default.
• W3000081737 cites W1673031009 @default.
• W3000081737 cites W1969965083 @default.
• W3000081737 cites W2016079550 @default.
• W3000081737 cites W2016833582 @default.
• W3000081737 cites W2028104399 @default.
• W3000081737 cites W2038161969 @default.
• W3000081737 cites W2038981426 @default.
• W3000081737 cites W2039201527 @default.
• W3000081737 cites W2047597898 @default.
• W3000081737 cites W2059999488 @default.
• W3000081737 cites W2064831267 @default.
• W3000081737 cites W2073140442 @default.
• W3000081737 cites W2094395262 @default.
• W3000081737 cites W2096336184 @default.
• W3000081737 cites W2097946794 @default.
• W3000081737 cites W2114947413 @default.
• W3000081737 cites W2127226843 @default.
• W3000081737 cites W2169758210 @default.
• W3000081737 cites W2189916683 @default.
• W3000081737 cites W2405325189 @default.
• W3000081737 cites W2566332174 @default.
• W3000081737 cites W2735790370 @default.
• W3000081737 cites W2754799078 @default.
• W3000081737 cites W2804360757 @default.
• W3000081737 cites W2806544610 @default.
• W3000081737 cites W2902050434 @default.
• W3000081737 cites W2912731704 @default.
• W3000081737 cites W2977497532 @default.
• W3000081737 cites W2977606681 @default.
• W3000081737 cites W4243449389 @default.
• W3000081737 cites W4250253048 @default.
• W3000081737 doi "https://doi.org/10.1001/jamaoncol.2019.5868" @default.
• W3000081737 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6990720" @default.
• W3000081737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31944221" @default.
• W3000081737 hasPublicationYear "2020" @default.
• W3000081737 type Work @default.
• W3000081737 sameAs 3000081737 @default.
• W3000081737 citedByCount "138" @default.
• W3000081737 countsByYear W30000817372020 @default.
• W3000081737 countsByYear W30000817372021 @default.
• W3000081737 countsByYear W30000817372022 @default.
• W3000081737 countsByYear W30000817372023 @default.
• W3000081737 crossrefType "journal-article" @default.
• W3000081737 hasAuthorship W3000081737A5000726024 @default.
• W3000081737 hasAuthorship W3000081737A5003759585 @default.
• W3000081737 hasAuthorship W3000081737A5006824054 @default.
• W3000081737 hasAuthorship W3000081737A5014676719 @default.
• W3000081737 hasAuthorship W3000081737A5018363328 @default.
• W3000081737 hasAuthorship W3000081737A5020088480 @default.
• W3000081737 hasAuthorship W3000081737A5020660748 @default.
• W3000081737 hasAuthorship W3000081737A5020924929 @default.
• W3000081737 hasAuthorship W3000081737A5024662505 @default.
• W3000081737 hasAuthorship W3000081737A5030981796 @default.
• W3000081737 hasAuthorship W3000081737A5033718291 @default.
• W3000081737 hasAuthorship W3000081737A5036392227 @default.
• W3000081737 hasAuthorship W3000081737A5036713963 @default.
• W3000081737 hasAuthorship W3000081737A5037796472 @default.
• W3000081737 hasAuthorship W3000081737A5038550266 @default.
• W3000081737 hasAuthorship W3000081737A5044030725 @default.
• W3000081737 hasAuthorship W3000081737A5044084703 @default.

• next